Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium
22. Juni 2021 08:00 ET
|
Artelo Biosciences
Dr. Andrew Yates to Present Poster on the Company’s ART27.13 Cancer Appetite Recovery Study Prof. Saoirse O’Sullivan to Present Poster Related to Artelo’s ART12.11 CBD Cocrystal and the Effects of...
Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th
02. Juni 2021 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate...
Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update
13. April 2021 08:30 ET
|
Artelo Biosciences
Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK Reported Positive Pre-Clinical Data Associated with Artelo’s Proprietary CBD Cocrystal $11.2 Million of Cash and...
Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
12. April 2021 08:30 ET
|
Artelo Biosciences
Initial safety data expected from CAReS Study before end of 2021 Targeting multi-billion market with no approved therapies for cancer-related anorexia LA JOLLA, Calif., April 12, 2021 (GLOBE...
Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
19. März 2021 10:00 ET
|
Artelo Biosciences
Detection of elevated FABP5 associated with additional tumor types suggests the target for ART26.12 may be more broadly relevant in cancer therapy Alderley Park Oncology Development Program is a UK...
Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors
09. März 2021 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target...
Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
02. März 2021 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling...
Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal
17. Februar 2021 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) today announced that Saoirse O’Sullivan, Ph.D., Professor of Pharmacology and Scientific Advisor to...
Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer
16. Februar 2021 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate...
Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants
08. Februar 2021 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling...